Aclidiniumbromid forbedrer lungefunktion og reducerer åndenöd hos patienter med KOL
Engelsk titel: Aclidinium bromide improves the lung function and reduces dyspnoea in patients with COPD
Läs online
Författare:
Ulrik, Charlotte Suppli
Email: csulrik@dadlnet.dk
Språk: Dan
Antal referenser: 22
Dokumenttyp:
Översikt
UI-nummer: 14087195
Sammanfattning
Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.